# Lino Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lino-biotech

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.lino-biotech.com
- Latest round: Seed (Nov 17, 2020)
- Investors on record: 2

## About

Lino Biotech AG develops advanced measurement technologies for biological interactions, emphasizing their flagship MACS® Matchmaker product, which enables detailed, label-free molecular characterization in real biological systems.Lino Biotech AG, founded in 2019, operates from Zurich, Switzerland, focusing on innovative technologies for biological interactions. The company has completed 2 deals, with its most recent deal occurring on March 22, 2023, when it was acquired by Miltenyi Biotec from High-Tech Gründerfonds and Roche Venture Fund. Andreas Frutiger is the founder, while Mirko Stange serves as the CEO.Lino Biotech AG specializes in advanced measurement technologies for biological interactions, with a focus on their flagship product, the MACS® Matchmaker, which utilizes focal Molography. This innovative technology enables label-free characterization of molecular dynamics in real biological systems, allowing researchers to observe and quantify biological processes without interference from labels or pre-purification steps. The company’s product offerings primarily target R&D labs in the biotech and pharmaceutical industries, facilitating applications such as antibody development and protein-protein interaction studies. The MACS® Matchmaker is designed to handle complex samples, providing high sensitivity measurements of small proteins and peptides, and can characterize multiple interactions simultaneously, significantly streamlining the experimental process. Lino Biotech serves a diverse client base across various regions, including North America, Europe, and Asia, catering to academic institutions, pharmaceutical companies, and contract research organizations.Lino Biotech AG generates revenue through the sale of its advanced instruments, sensor chips, and associated kits, focusing on B2B transactions with research institutions and biotech companies. The company’s revenue model is centered on direct sales of its products, including bulk purchasing options or subscription-based access for ongoing support and maintenance services. The MACS® Matchmaker and its related products are essential for clients involved in high-throughput research and development, facilitating efficient workflows in biologically relevant conditions. Transactional activities typically involve contracts outlining pricing for instruments and consumables, which can vary based on the scope and scale of the research projects undertaken by the clients.Following its acquisition on March 22, 2023, by Miltenyi Biotec, Lino Biotech AG intends to expand its product line, focusing on new measurement technologies designed for specific applications in the biotech sector. The company plans to broaden its market presence in North America and Asia by the end of 2024, leveraging synergies from the acquisition to enhance its distribution capabilities. Recent funding from the acquisition will be utilized to support these initiatives, allowing for increased investment in research and development and the establishment of stronger market connections.

## Funding rounds

- Seed, Nov 17, 2020 — Roche Venture Fund, High-Tech Gruenderfonds

## Investors

- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Seed
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed